Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are glucose-lowering agents that decrease hyperglycemia by inhibiting SGLT2 in the proximal tubule of the kidney, which is responsible for the reabsorption of filtered glucose [7,8]. Here, SLC5A2 is linked to Hyperglycemia.